首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Atomic absorption spectrometric determination of the iridium content in tumor cells exposed to an iridium metallodrug.
【24h】

Atomic absorption spectrometric determination of the iridium content in tumor cells exposed to an iridium metallodrug.

机译:原子吸收光谱法测定暴露于铱金属药物的肿瘤细胞中的铱含量。

获取原文
获取原文并翻译 | 示例
           

摘要

An electrothermal atomic absorption spectrometric method to quantify the iridium content of HT-29 colon carcinoma cells exposed to iridium metallodrugs was developed. Optimisation of the procedure involved the evaluation of pyrolysis and atomisation conditions (optimal values were 1400 degrees C for pyrolysis and 2400 degrees C for atomisation) and the addition of appropriate additives. The presence of cellular components as well as the addition of nitric acid and hydrochloric acid led to enhanced absorption signals and suggested the use of matrix matched calibration. The described method allows the measurement of iridium in cell suspensions in the low microg/L range (linear dynamic range: 10-450 microg/L) with a detection limit of 11.2 microg/L. The applicability of the method was tested by means of a novel iridium metallodrug. First results on the complex [IrCl3(DMSO)(phen)] indicated a low cellular uptake (21.2 microM at incubation with 100 microM) of this iridium species in HT-29 cells compared to other metal containing antitumor drugs.
机译:提出了一种电热原子吸收光谱法,用于定量测定暴露于铱金属药物的HT-29结肠癌细胞中的铱含量。程序的优化涉及热解和雾化条件的评估(热解的最佳值为1400℃,雾化的最佳值为2400℃),并添加适当的添加剂。细胞成分的存在以及硝酸和盐酸的加入导致吸收信号增强,并建议使用基质匹配的校准方法。所描述的方法允许以低的microg / L范围(线性动态范围:10-450 microg / L)测量细胞悬浮液中的铱,检测限为11.2 microg / L。该方法的适用性通过新型铱金属药物进行了测试。与其他含金属的抗肿瘤药物相比,复合物[IrCl3(DMSO)(phen)]的初步结果表明,该铱物种在HT-29细胞中的细胞摄取量较低(与100 microM孵育时为21.2 microM)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号